IMCgp100-203 https://www.nct-dresden.de/en/trials/900-000002304 https://www.nct-dresden.de/@@site-logo/logo-nct.svg IMCgp100-203 Category Skin tumors Subcategory Melanoma Trial Type Follow-Up Treatment (Metastatic Disease) Description for experts Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM) Description for laymen
